Understanding and optimizing automation in cell therapy manufacture: an interview with Synthace

Written by RegMedNet

Learn more about the role that automation could play in cell manufacturing of the future in this podcast interview with Markus Gershater, Chief Scientific Officer, Synthace (London, UK).

Cell and gene therapy manufacturers have been keen to implement automation in their workflows to make their processes more efficient, effective and reliable. However, automation is more than just a closed system.

In this interview, part of the latest RegMedNet spotlight on automation, we spoke to Markus Gershater, Chief Scientific Officer, Synthace (London, UK). In this podcast, we discuss the numerous ways automation could enable new approaches to science, what digital tools are needed to get the most out of your automated workflow and whether humans have a place in cell and gene therapy manufacture.

To find out more about automation in the cell and gene therapy workflow, visit our spotlight now>>